StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Other equities analysts have also recently issued reports about the company. D. Boral Capital restated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a report on Thursday, February 6th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.63 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.11. The stock has a market cap of $58.10 million, a PE ratio of -1.74 and a beta of 1.20. The business’s fifty day moving average is $0.62 and its 200-day moving average is $0.65.

Insider Transactions at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 358,266 shares of company stock worth $204,212. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ground Swell Capital LLC grew its stake in shares of VolitionRx by 78.8% in the 3rd quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock valued at $28,000 after purchasing an additional 20,249 shares during the period. Geode Capital Management LLC grew its stake in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the period. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at approximately $29,000. Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Finally, Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.